List view / Grid view

Onyx Pharmaceuticals Inc.

Amgen announces top-line results from Phase 3 focus trial of kyprolis® in patients with relapsed and advanced refractory multiple myeloma

15 August 2014 | By Amgen

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that the Phase 3 clinical trial FOCUS did not meet its primary endpoint of improving overall survival...

news

Amgen and Onyx Data at ASCO 2014 highlight oncology pipeline and portfolio

28 May 2014 | By Amgen

New data reinforces commitment to personalized medicine and highlights advances in immunotherapy platform...

news

Bayer and Onyx report Phase 3 study results of NEXAVAR® (sorafenib) as adjuvant treatment for patients with liver cancer who have undergone surgery or local ablation

11 March 2014 | By Amgen

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma...

news

U.S. FDA Approves NEXAVAR® (sorafenib) for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment

22 November 2013 | By Amgen

First and only FDA-approved treatment option for patients with this type of thyroid cancer...

news

Amgen and Onyx Pharmaceuticals announce early termination of HSR waiting period

18 September 2013 | By Amgen

Amgen and Onyx Pharmaceuticals have announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Amgen's proposed acquisition of Onyx, was terminated early on Sept. 18, 2013...

news

Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash

25 August 2013 | By Amgen

Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash...

news

Nexavar in combination with chemotherapy improves progression-free survival in patients with advanced breast cancer in Phase 2 study

18 May 2011 | By OGILVY PR WORLDWIDE

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. announced results from a Phase 2b trial...

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Onyx Pharmaceuticals Inc.

Amgen announces top-line results from Phase 3 focus trial of kyprolis® in patients with relapsed and advanced refractory multiple myeloma

Amgen and Onyx Data at ASCO 2014 highlight oncology pipeline and portfolio

Bayer and Onyx report Phase 3 study results of NEXAVAR® (sorafenib) as adjuvant treatment for patients with liver cancer who have undergone surgery or local ablation

U.S. FDA Approves NEXAVAR® (sorafenib) for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment

Amgen and Onyx Pharmaceuticals announce early termination of HSR waiting period

Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash

Nexavar in combination with chemotherapy improves progression-free survival in patients with advanced breast cancer in Phase 2 study